Prostate cancer
Conditions
Interventions
Index test:Ultrasound 
combined 
with 
and 
distribution
Sponsors
Department of urology, The First Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who were clinically diagnosed with prostate cancer and met the conditions of neoadjuvant therapy, the conditions were as follows: (1) Locally advanced prostate cancer at initial diagnosis (stage T3~T4 or stage N of any T stage); (2) According to the 2021 National Comprehensive Cancer Network (NCCN) Clinical guidelines for prostate cancer risk classification, patients were classified as extremely high risk at initial diagnosis [at least one of the following must be met: STAGE T3b to T4; Gleason score 5 in the major grading area of prostate cancer tissue; puncture > 4 needles were classified into 4 or 5 groups according to ISUP grading; biopsy > 4 needles were classified into 4 or 5 groups according to ISUP grading. Characteristics of more than 2 high-risk groups]; (3) No distant metastasis was confirmed by whole-body bone imaging or positron emission tomography/computed tomography (PET/CT) at initial diagnosis. 2. Patients who underwent ultrasound elastography and body fat muscle distribution testing before receiving neoadjuvant therapy; 3. Complete clinicopathological data; 4. ECOG physical fitness status score 0-2; 5. Male patients aged 18 to 75 years; 6. Function of major organs: liver, kidney, bone marrow, heart and other important organs have no obvious abnormality; 7. The subject must have the ability to understand and sign the informed consent voluntarily, and the informed consent must be signed before any test procedures; 8. No malignant tumors other than prostate cancer were found at initial diagnosis.
Exclusion criteria
Exclusion criteria: 1. Abnormal coagulation mechanism; 2. Patients who had received other adjuvant chemotherapy such as chemotherapy, radiotherapy and immunotherapy before neoadjuvant therapy; 3. Have a history of severe allergic reactions to chemotherapy drugs and contrast agents; 4. acute infection of urinary system; 5. Serious organ dysfunction, such as serious abnormality of heart, lung, liver and kidney; 6. Incomplete data and information collection; 7. persons suffering from diseases or infections related to human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); 8. Patients who abuse alcohol or narcotic drugs, have a history of drug abuse, or have a history of mental illness; 9. Patients who cannot cooperate with relevant examinations of this project and do not agree to sign informed consent; 10. Patients with the following symptoms within 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack; 11. Patients with persistent arrhythmia grade >= 2 (NCI CTCAE Version 4.0 grade); 12. Patients with claustrophobia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body Mass Index (BMI);Elastography;Skeletal Muscle Index (SMI);Skeletal Muscle Density(SMD);Subcutaneous Fat Area (SFA);Visceral Fat Area (VFA);Periprostatic Fat Area (PPFA);Periprostatic Fat Area/Prostate Area(PPFA/PA);Periprostatic Fat Thickness/Subcutaneous Fat Thickness (PPFT/SFT);Waist Circumference(WC);Hip circumferenc(HC);Waist-hip ratio(WHR);Subcutaneous Fat Index(SFI);Subcutaneous Fat Thickness(SFT);Visceral Fat Index(VFI); | — |
Countries
China
Contacts
Public ContactNing Xu
Outcome results
None listed